nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Irinotecan—colon cancer	0.282	1	CrCtD
Topotecan—Topoisomerase Inhibitors—Irinotecan—colon cancer	0.256	1	CiPCiCtD
Topotecan—TOP1—colon cancer	0.127	0.893	CbGaD
Topotecan—ovarian cancer—colon cancer	0.0872	0.553	CtDrD
Topotecan—TOP1MT—Irinotecan—colon cancer	0.0769	0.547	CbGbCtD
Topotecan—lung cancer—colon cancer	0.0704	0.447	CtDrD
Topotecan—TOP1—Irinotecan—colon cancer	0.0442	0.314	CbGbCtD
Topotecan—ABCB1—colon cancer	0.0151	0.106	CbGaD
Topotecan—ABCG2—Irinotecan—colon cancer	0.00419	0.0298	CbGbCtD
Topotecan—ABCG2—Fluorouracil—colon cancer	0.00402	0.0286	CbGbCtD
Topotecan—ABCG2—Vincristine—colon cancer	0.00366	0.0261	CbGbCtD
Topotecan—ABCG2—Methotrexate—colon cancer	0.00222	0.0158	CbGbCtD
Topotecan—ABCB1—Irinotecan—colon cancer	0.00151	0.0108	CbGbCtD
Topotecan—ABCB1—Vincristine—colon cancer	0.00132	0.0094	CbGbCtD
Topotecan—Irinotecan—TOP1—colon cancer	0.000982	0.894	CrCbGaD
Topotecan—CYP3A4—Irinotecan—colon cancer	0.000905	0.00644	CbGbCtD
Topotecan—ABCB1—Methotrexate—colon cancer	0.0008	0.00569	CbGbCtD
Topotecan—CYP3A4—Vincristine—colon cancer	0.000791	0.00563	CbGbCtD
Topotecan—ABCG2—Abacavir transmembrane transport—ABCB1—colon cancer	0.000133	0.0834	CbGpPWpGaD
Topotecan—Irinotecan—ABCB1—colon cancer	0.000117	0.106	CrCbGaD
Topotecan—TOP1MT—liver—colon cancer	0.000113	0.131	CbGeAlD
Topotecan—TOP1—smooth muscle tissue—colon cancer	0.000101	0.117	CbGeAlD
Topotecan—TOP1—Caspase Cascade in Apoptosis—BAX—colon cancer	9.41e-05	0.0592	CbGpPWpGaD
Topotecan—TOP1MT—lymph node—colon cancer	8.63e-05	0.1	CbGeAlD
Topotecan—TOP1—Caspase Cascade in Apoptosis—BCL2L1—colon cancer	8.17e-05	0.0514	CbGpPWpGaD
Topotecan—ABCG2—Abacavir transport and metabolism—ABCB1—colon cancer	7.62e-05	0.0479	CbGpPWpGaD
Topotecan—TOP1—bone marrow—colon cancer	7.35e-05	0.0852	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	7.2e-05	0.0453	CbGpPWpGaD
Topotecan—TOP1—vagina—colon cancer	7.04e-05	0.0816	CbGeAlD
Topotecan—Sweating—Irinotecan—colon cancer	6.31e-05	0.0034	CcSEcCtD
Topotecan—Infestation—Fluorouracil—colon cancer	6.31e-05	0.0034	CcSEcCtD
Topotecan—Infestation NOS—Fluorouracil—colon cancer	6.31e-05	0.0034	CcSEcCtD
Topotecan—Neuropathy peripheral—Fluorouracil—colon cancer	6.18e-05	0.00333	CcSEcCtD
Topotecan—Stomatitis—Fluorouracil—colon cancer	6.15e-05	0.00331	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	6.06e-05	0.0381	CbGpPWpGaD
Topotecan—Hypoaesthesia—Vincristine—colon cancer	6.04e-05	0.00325	CcSEcCtD
Topotecan—Dermatitis bullous—Capecitabine—colon cancer	5.99e-05	0.00322	CcSEcCtD
Topotecan—Respiratory failure—Methotrexate—colon cancer	5.97e-05	0.00322	CcSEcCtD
Topotecan—Epistaxis—Fluorouracil—colon cancer	5.95e-05	0.0032	CcSEcCtD
Topotecan—Haemoglobin—Irinotecan—colon cancer	5.94e-05	0.0032	CcSEcCtD
Topotecan—TOP1—liver—colon cancer	5.94e-05	0.0689	CbGeAlD
Topotecan—Rhinitis—Irinotecan—colon cancer	5.93e-05	0.00319	CcSEcCtD
Topotecan—Haemorrhage—Irinotecan—colon cancer	5.91e-05	0.00318	CcSEcCtD
Topotecan—Pulmonary embolism—Methotrexate—colon cancer	5.87e-05	0.00316	CcSEcCtD
Topotecan—Lethargy—Capecitabine—colon cancer	5.84e-05	0.00314	CcSEcCtD
Topotecan—Haemoglobin—Fluorouracil—colon cancer	5.69e-05	0.00306	CcSEcCtD
Topotecan—Rhinitis—Fluorouracil—colon cancer	5.68e-05	0.00306	CcSEcCtD
Topotecan—Haemorrhage—Fluorouracil—colon cancer	5.66e-05	0.00305	CcSEcCtD
Topotecan—Hypoaesthesia—Fluorouracil—colon cancer	5.63e-05	0.00303	CcSEcCtD
Topotecan—Pharyngitis—Fluorouracil—colon cancer	5.62e-05	0.00303	CcSEcCtD
Topotecan—Angiopathy—Vincristine—colon cancer	5.51e-05	0.00297	CcSEcCtD
Topotecan—Mediastinal disorder—Vincristine—colon cancer	5.47e-05	0.00295	CcSEcCtD
Topotecan—Cardiac arrest—Capecitabine—colon cancer	5.44e-05	0.00293	CcSEcCtD
Topotecan—Alopecia—Vincristine—colon cancer	5.36e-05	0.00289	CcSEcCtD
Topotecan—Angiopathy—Irinotecan—colon cancer	5.36e-05	0.00289	CcSEcCtD
Topotecan—Immune system disorder—Irinotecan—colon cancer	5.34e-05	0.00288	CcSEcCtD
Topotecan—Mediastinal disorder—Irinotecan—colon cancer	5.33e-05	0.00287	CcSEcCtD
Topotecan—Chills—Irinotecan—colon cancer	5.31e-05	0.00286	CcSEcCtD
Topotecan—Neoplasm—Methotrexate—colon cancer	5.3e-05	0.00286	CcSEcCtD
Topotecan—Alopecia—Irinotecan—colon cancer	5.22e-05	0.00281	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Capecitabine—colon cancer	5.15e-05	0.00277	CcSEcCtD
Topotecan—Back pain—Vincristine—colon cancer	5.11e-05	0.00275	CcSEcCtD
Topotecan—Sepsis—Methotrexate—colon cancer	5.09e-05	0.00274	CcSEcCtD
Topotecan—TOP1—Caspase Cascade in Apoptosis—CASP3—colon cancer	5.05e-05	0.0318	CbGpPWpGaD
Topotecan—Alanine aminotransferase increased—Capecitabine—colon cancer	5.05e-05	0.00272	CcSEcCtD
Topotecan—Alopecia—Fluorouracil—colon cancer	5e-05	0.00269	CcSEcCtD
Topotecan—Back pain—Irinotecan—colon cancer	4.98e-05	0.00268	CcSEcCtD
Topotecan—Muscle spasms—Irinotecan—colon cancer	4.95e-05	0.00266	CcSEcCtD
Topotecan—Anaemia—Vincristine—colon cancer	4.88e-05	0.00263	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	4.84e-05	0.0305	CbGpPWpGaD
Topotecan—Ill-defined disorder—Irinotecan—colon cancer	4.78e-05	0.00257	CcSEcCtD
Topotecan—Anaemia—Irinotecan—colon cancer	4.76e-05	0.00256	CcSEcCtD
Topotecan—Leukopenia—Vincristine—colon cancer	4.73e-05	0.00255	CcSEcCtD
Topotecan—Pancytopenia—Capecitabine—colon cancer	4.7e-05	0.00253	CcSEcCtD
Topotecan—Malaise—Irinotecan—colon cancer	4.64e-05	0.0025	CcSEcCtD
Topotecan—Neutropenia—Capecitabine—colon cancer	4.62e-05	0.00249	CcSEcCtD
Topotecan—Leukopenia—Irinotecan—colon cancer	4.61e-05	0.00248	CcSEcCtD
Topotecan—Anaemia—Fluorouracil—colon cancer	4.56e-05	0.00245	CcSEcCtD
Topotecan—TOP1—lymph node—colon cancer	4.55e-05	0.0528	CbGeAlD
Topotecan—Myalgia—Vincristine—colon cancer	4.5e-05	0.00242	CcSEcCtD
Topotecan—Weight increased—Capecitabine—colon cancer	4.5e-05	0.00242	CcSEcCtD
Topotecan—Cough—Irinotecan—colon cancer	4.49e-05	0.00242	CcSEcCtD
Topotecan—Pneumonia—Capecitabine—colon cancer	4.43e-05	0.00239	CcSEcCtD
Topotecan—Leukopenia—Fluorouracil—colon cancer	4.41e-05	0.00238	CcSEcCtD
Topotecan—Infestation NOS—Capecitabine—colon cancer	4.41e-05	0.00237	CcSEcCtD
Topotecan—Infestation—Capecitabine—colon cancer	4.41e-05	0.00237	CcSEcCtD
Topotecan—Anaphylactoid reaction—Methotrexate—colon cancer	4.4e-05	0.00237	CcSEcCtD
Topotecan—Lethargy—Methotrexate—colon cancer	4.35e-05	0.00234	CcSEcCtD
Topotecan—Discomfort—Irinotecan—colon cancer	4.33e-05	0.00233	CcSEcCtD
Topotecan—Neuropathy peripheral—Capecitabine—colon cancer	4.32e-05	0.00233	CcSEcCtD
Topotecan—Anaphylactic shock—Vincristine—colon cancer	4.31e-05	0.00232	CcSEcCtD
Topotecan—Stomatitis—Capecitabine—colon cancer	4.3e-05	0.00231	CcSEcCtD
Topotecan—Infection—Vincristine—colon cancer	4.29e-05	0.00231	CcSEcCtD
Topotecan—Nervous system disorder—Vincristine—colon cancer	4.23e-05	0.00228	CcSEcCtD
Topotecan—Thrombocytopenia—Vincristine—colon cancer	4.22e-05	0.00227	CcSEcCtD
Topotecan—Anaphylactic shock—Irinotecan—colon cancer	4.2e-05	0.00226	CcSEcCtD
Topotecan—Myalgia—Fluorouracil—colon cancer	4.2e-05	0.00226	CcSEcCtD
Topotecan—Chest pain—Fluorouracil—colon cancer	4.2e-05	0.00226	CcSEcCtD
Topotecan—ABCG2—Irinotecan Pathway—APC—colon cancer	4.19e-05	0.0264	CbGpPWpGaD
Topotecan—Infection—Irinotecan—colon cancer	4.17e-05	0.00225	CcSEcCtD
Topotecan—Hyperhidrosis—Vincristine—colon cancer	4.17e-05	0.00225	CcSEcCtD
Topotecan—Hepatobiliary disease—Capecitabine—colon cancer	4.17e-05	0.00224	CcSEcCtD
Topotecan—Epistaxis—Capecitabine—colon cancer	4.16e-05	0.00224	CcSEcCtD
Topotecan—Discomfort—Fluorouracil—colon cancer	4.15e-05	0.00223	CcSEcCtD
Topotecan—Nervous system disorder—Irinotecan—colon cancer	4.12e-05	0.00222	CcSEcCtD
Topotecan—Thrombocytopenia—Irinotecan—colon cancer	4.11e-05	0.00221	CcSEcCtD
Topotecan—Anorexia—Vincristine—colon cancer	4.11e-05	0.00221	CcSEcCtD
Topotecan—Hyperhidrosis—Irinotecan—colon cancer	4.06e-05	0.00219	CcSEcCtD
Topotecan—Anaphylactic shock—Fluorouracil—colon cancer	4.02e-05	0.00217	CcSEcCtD
Topotecan—Anorexia—Irinotecan—colon cancer	4e-05	0.00216	CcSEcCtD
Topotecan—Infection—Fluorouracil—colon cancer	4e-05	0.00215	CcSEcCtD
Topotecan—Haemoglobin—Capecitabine—colon cancer	3.98e-05	0.00214	CcSEcCtD
Topotecan—Rhinitis—Capecitabine—colon cancer	3.97e-05	0.00214	CcSEcCtD
Topotecan—Haemorrhage—Capecitabine—colon cancer	3.96e-05	0.00213	CcSEcCtD
Topotecan—Nervous system disorder—Fluorouracil—colon cancer	3.95e-05	0.00212	CcSEcCtD
Topotecan—Thrombocytopenia—Fluorouracil—colon cancer	3.94e-05	0.00212	CcSEcCtD
Topotecan—Hypoaesthesia—Capecitabine—colon cancer	3.94e-05	0.00212	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Vincristine—colon cancer	3.93e-05	0.00212	CcSEcCtD
Topotecan—Pharyngitis—Capecitabine—colon cancer	3.93e-05	0.00211	CcSEcCtD
Topotecan—Paraesthesia—Vincristine—colon cancer	3.87e-05	0.00209	CcSEcCtD
Topotecan—Anorexia—Fluorouracil—colon cancer	3.83e-05	0.00206	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	3.78e-05	0.0238	CbGpPWpGaD
Topotecan—Paraesthesia—Irinotecan—colon cancer	3.77e-05	0.00203	CcSEcCtD
Topotecan—ABCB1—blood vessel—colon cancer	3.77e-05	0.0437	CbGeAlD
Topotecan—Decreased appetite—Vincristine—colon cancer	3.75e-05	0.00202	CcSEcCtD
Topotecan—Dyspnoea—Irinotecan—colon cancer	3.75e-05	0.00202	CcSEcCtD
Topotecan—Gastrointestinal disorder—Vincristine—colon cancer	3.72e-05	0.002	CcSEcCtD
Topotecan—Fatigue—Vincristine—colon cancer	3.72e-05	0.002	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	3.71e-05	0.0234	CbGpPWpGaD
Topotecan—Dyspepsia—Irinotecan—colon cancer	3.7e-05	0.00199	CcSEcCtD
Topotecan—Constipation—Vincristine—colon cancer	3.69e-05	0.00199	CcSEcCtD
Topotecan—Pain—Vincristine—colon cancer	3.69e-05	0.00199	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Fluorouracil—colon cancer	3.67e-05	0.00197	CcSEcCtD
Topotecan—Decreased appetite—Irinotecan—colon cancer	3.65e-05	0.00197	CcSEcCtD
Topotecan—Gastrointestinal disorder—Irinotecan—colon cancer	3.63e-05	0.00195	CcSEcCtD
Topotecan—Fatigue—Irinotecan—colon cancer	3.62e-05	0.00195	CcSEcCtD
Topotecan—Paraesthesia—Fluorouracil—colon cancer	3.61e-05	0.00195	CcSEcCtD
Topotecan—Pain—Irinotecan—colon cancer	3.59e-05	0.00193	CcSEcCtD
Topotecan—Constipation—Irinotecan—colon cancer	3.59e-05	0.00193	CcSEcCtD
Topotecan—Angiopathy—Capecitabine—colon cancer	3.59e-05	0.00193	CcSEcCtD
Topotecan—Dyspnoea—Fluorouracil—colon cancer	3.59e-05	0.00193	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	3.58e-05	0.0225	CbGpPWpGaD
Topotecan—Immune system disorder—Capecitabine—colon cancer	3.57e-05	0.00192	CcSEcCtD
Topotecan—Mediastinal disorder—Capecitabine—colon cancer	3.57e-05	0.00192	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—TYMS—colon cancer	3.56e-05	0.0224	CbGpPWpGaD
Topotecan—Chills—Capecitabine—colon cancer	3.55e-05	0.00191	CcSEcCtD
Topotecan—Dyspepsia—Fluorouracil—colon cancer	3.54e-05	0.00191	CcSEcCtD
Topotecan—Gastrointestinal pain—Vincristine—colon cancer	3.53e-05	0.0019	CcSEcCtD
Topotecan—Decreased appetite—Fluorouracil—colon cancer	3.5e-05	0.00188	CcSEcCtD
Topotecan—Alopecia—Capecitabine—colon cancer	3.5e-05	0.00188	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—colon cancer	3.5e-05	0.00188	CcSEcCtD
Topotecan—Gastrointestinal disorder—Fluorouracil—colon cancer	3.47e-05	0.00187	CcSEcCtD
Topotecan—Feeling abnormal—Irinotecan—colon cancer	3.46e-05	0.00186	CcSEcCtD
Topotecan—Malnutrition—Capecitabine—colon cancer	3.44e-05	0.00185	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—colon cancer	3.44e-05	0.00185	CcSEcCtD
Topotecan—Pain—Fluorouracil—colon cancer	3.44e-05	0.00185	CcSEcCtD
Topotecan—Gastrointestinal pain—Irinotecan—colon cancer	3.43e-05	0.00185	CcSEcCtD
Topotecan—Abdominal pain—Vincristine—colon cancer	3.41e-05	0.00184	CcSEcCtD
Topotecan—Body temperature increased—Vincristine—colon cancer	3.41e-05	0.00184	CcSEcCtD
Topotecan—Back pain—Capecitabine—colon cancer	3.33e-05	0.00179	CcSEcCtD
Topotecan—Body temperature increased—Irinotecan—colon cancer	3.32e-05	0.00179	CcSEcCtD
Topotecan—Abdominal pain—Irinotecan—colon cancer	3.32e-05	0.00179	CcSEcCtD
Topotecan—Feeling abnormal—Fluorouracil—colon cancer	3.32e-05	0.00179	CcSEcCtD
Topotecan—Muscle spasms—Capecitabine—colon cancer	3.31e-05	0.00178	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—colon cancer	3.3e-05	0.00178	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—colon cancer	3.28e-05	0.00177	CcSEcCtD
Topotecan—Infestation—Methotrexate—colon cancer	3.28e-05	0.00177	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—colon cancer	3.2e-05	0.00172	CcSEcCtD
Topotecan—Ill-defined disorder—Capecitabine—colon cancer	3.2e-05	0.00172	CcSEcCtD
Topotecan—Urticaria—Fluorouracil—colon cancer	3.2e-05	0.00172	CcSEcCtD
Topotecan—Anaemia—Capecitabine—colon cancer	3.18e-05	0.00171	CcSEcCtD
Topotecan—Body temperature increased—Fluorouracil—colon cancer	3.18e-05	0.00171	CcSEcCtD
Topotecan—Hypersensitivity—Vincristine—colon cancer	3.18e-05	0.00171	CcSEcCtD
Topotecan—Sweating—Methotrexate—colon cancer	3.15e-05	0.00169	CcSEcCtD
Topotecan—Malaise—Capecitabine—colon cancer	3.11e-05	0.00167	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—colon cancer	3.1e-05	0.00167	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—colon cancer	3.1e-05	0.00167	CcSEcCtD
Topotecan—Hypersensitivity—Irinotecan—colon cancer	3.09e-05	0.00167	CcSEcCtD
Topotecan—Asthenia—Vincristine—colon cancer	3.09e-05	0.00167	CcSEcCtD
Topotecan—Leukopenia—Capecitabine—colon cancer	3.08e-05	0.00166	CcSEcCtD
Topotecan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	3.03e-05	0.0191	CbGpPWpGaD
Topotecan—Asthenia—Irinotecan—colon cancer	3.01e-05	0.00162	CcSEcCtD
Topotecan—Cough—Capecitabine—colon cancer	3.01e-05	0.00162	CcSEcCtD
Topotecan—Hypersensitivity—Fluorouracil—colon cancer	2.96e-05	0.0016	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—colon cancer	2.96e-05	0.00159	CcSEcCtD
Topotecan—Diarrhoea—Vincristine—colon cancer	2.95e-05	0.00159	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—colon cancer	2.95e-05	0.00159	CcSEcCtD
Topotecan—Arthralgia—Capecitabine—colon cancer	2.93e-05	0.00158	CcSEcCtD
Topotecan—Chest pain—Capecitabine—colon cancer	2.93e-05	0.00158	CcSEcCtD
Topotecan—Myalgia—Capecitabine—colon cancer	2.93e-05	0.00158	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—colon cancer	2.92e-05	0.00157	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	2.91e-05	0.00157	CcSEcCtD
Topotecan—Discomfort—Capecitabine—colon cancer	2.9e-05	0.00156	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—TYMS—colon cancer	2.88e-05	0.0181	CbGpPWpGaD
Topotecan—Diarrhoea—Irinotecan—colon cancer	2.87e-05	0.00155	CcSEcCtD
Topotecan—Dizziness—Vincristine—colon cancer	2.85e-05	0.00154	CcSEcCtD
Topotecan—Pruritus—Fluorouracil—colon cancer	2.85e-05	0.00153	CcSEcCtD
Topotecan—Infection—Capecitabine—colon cancer	2.79e-05	0.0015	CcSEcCtD
Topotecan—Dizziness—Irinotecan—colon cancer	2.78e-05	0.0015	CcSEcCtD
Topotecan—Nervous system disorder—Capecitabine—colon cancer	2.76e-05	0.00148	CcSEcCtD
Topotecan—Diarrhoea—Fluorouracil—colon cancer	2.75e-05	0.00148	CcSEcCtD
Topotecan—Thrombocytopenia—Capecitabine—colon cancer	2.75e-05	0.00148	CcSEcCtD
Topotecan—Vomiting—Vincristine—colon cancer	2.74e-05	0.00148	CcSEcCtD
Topotecan—TOP1—Caspase Cascade in Apoptosis—AKT1—colon cancer	2.74e-05	0.0172	CbGpPWpGaD
Topotecan—Skin disorder—Capecitabine—colon cancer	2.73e-05	0.00147	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.72e-05	0.0171	CbGpPWpGaD
Topotecan—Rash—Vincristine—colon cancer	2.72e-05	0.00146	CcSEcCtD
Topotecan—Hyperhidrosis—Capecitabine—colon cancer	2.72e-05	0.00146	CcSEcCtD
Topotecan—Dermatitis—Vincristine—colon cancer	2.72e-05	0.00146	CcSEcCtD
Topotecan—Headache—Vincristine—colon cancer	2.7e-05	0.00145	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HNF4A—colon cancer	2.7e-05	0.017	CbGpPWpGaD
Topotecan—Anorexia—Capecitabine—colon cancer	2.68e-05	0.00144	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—colon cancer	2.67e-05	0.00144	CcSEcCtD
Topotecan—Vomiting—Irinotecan—colon cancer	2.67e-05	0.00144	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—colon cancer	2.66e-05	0.00143	CcSEcCtD
Topotecan—Dizziness—Fluorouracil—colon cancer	2.66e-05	0.00143	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—colon cancer	2.65e-05	0.00143	CcSEcCtD
Topotecan—Rash—Irinotecan—colon cancer	2.65e-05	0.00143	CcSEcCtD
Topotecan—Dermatitis—Irinotecan—colon cancer	2.65e-05	0.00142	CcSEcCtD
Topotecan—Chills—Methotrexate—colon cancer	2.64e-05	0.00142	CcSEcCtD
Topotecan—Headache—Irinotecan—colon cancer	2.63e-05	0.00142	CcSEcCtD
Topotecan—ABCG2—bone marrow—colon cancer	2.61e-05	0.0302	CbGeAlD
Topotecan—Alopecia—Methotrexate—colon cancer	2.6e-05	0.0014	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—colon cancer	2.56e-05	0.00138	CcSEcCtD
Topotecan—Nausea—Vincristine—colon cancer	2.56e-05	0.00138	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Capecitabine—colon cancer	2.56e-05	0.00138	CcSEcCtD
Topotecan—Vomiting—Fluorouracil—colon cancer	2.56e-05	0.00138	CcSEcCtD
Topotecan—Rash—Fluorouracil—colon cancer	2.54e-05	0.00137	CcSEcCtD
Topotecan—Dermatitis—Fluorouracil—colon cancer	2.53e-05	0.00136	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—PPARG—colon cancer	2.52e-05	0.0159	CbGpPWpGaD
Topotecan—Paraesthesia—Capecitabine—colon cancer	2.52e-05	0.00136	CcSEcCtD
Topotecan—Headache—Fluorouracil—colon cancer	2.52e-05	0.00136	CcSEcCtD
Topotecan—Dyspnoea—Capecitabine—colon cancer	2.51e-05	0.00135	CcSEcCtD
Topotecan—ABCG2—vagina—colon cancer	2.5e-05	0.029	CbGeAlD
Topotecan—Nausea—Irinotecan—colon cancer	2.5e-05	0.00134	CcSEcCtD
Topotecan—Back pain—Methotrexate—colon cancer	2.48e-05	0.00134	CcSEcCtD
Topotecan—Dyspepsia—Capecitabine—colon cancer	2.47e-05	0.00133	CcSEcCtD
Topotecan—Decreased appetite—Capecitabine—colon cancer	2.44e-05	0.00132	CcSEcCtD
Topotecan—Gastrointestinal disorder—Capecitabine—colon cancer	2.43e-05	0.00131	CcSEcCtD
Topotecan—Fatigue—Capecitabine—colon cancer	2.42e-05	0.00131	CcSEcCtD
Topotecan—Constipation—Capecitabine—colon cancer	2.4e-05	0.00129	CcSEcCtD
Topotecan—Pain—Capecitabine—colon cancer	2.4e-05	0.00129	CcSEcCtD
Topotecan—CYP3A4—renal system—colon cancer	2.4e-05	0.0279	CbGeAlD
Topotecan—Nausea—Fluorouracil—colon cancer	2.39e-05	0.00129	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—colon cancer	2.38e-05	0.00128	CcSEcCtD
Topotecan—Anaemia—Methotrexate—colon cancer	2.37e-05	0.00128	CcSEcCtD
Topotecan—Feeling abnormal—Capecitabine—colon cancer	2.32e-05	0.00125	CcSEcCtD
Topotecan—Malaise—Methotrexate—colon cancer	2.31e-05	0.00125	CcSEcCtD
Topotecan—Gastrointestinal pain—Capecitabine—colon cancer	2.3e-05	0.00124	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—colon cancer	2.3e-05	0.00124	CcSEcCtD
Topotecan—ABCB1—embryo—colon cancer	2.25e-05	0.026	CbGeAlD
Topotecan—Cough—Methotrexate—colon cancer	2.24e-05	0.0012	CcSEcCtD
Topotecan—Urticaria—Capecitabine—colon cancer	2.23e-05	0.0012	CcSEcCtD
Topotecan—Abdominal pain—Capecitabine—colon cancer	2.22e-05	0.0012	CcSEcCtD
Topotecan—Body temperature increased—Capecitabine—colon cancer	2.22e-05	0.0012	CcSEcCtD
Topotecan—Chest pain—Methotrexate—colon cancer	2.18e-05	0.00118	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—colon cancer	2.18e-05	0.00118	CcSEcCtD
Topotecan—Myalgia—Methotrexate—colon cancer	2.18e-05	0.00118	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	2.17e-05	0.00117	CcSEcCtD
Topotecan—Discomfort—Methotrexate—colon cancer	2.16e-05	0.00116	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—colon cancer	2.14e-05	0.0134	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	2.12e-05	0.0133	CbGpPWpGaD
Topotecan—ABCG2—liver—colon cancer	2.11e-05	0.0244	CbGeAlD
Topotecan—Anaphylactic shock—Methotrexate—colon cancer	2.09e-05	0.00113	CcSEcCtD
Topotecan—Infection—Methotrexate—colon cancer	2.08e-05	0.00112	CcSEcCtD
Topotecan—Hypersensitivity—Capecitabine—colon cancer	2.07e-05	0.00112	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.07e-05	0.013	CbGpPWpGaD
Topotecan—Nervous system disorder—Methotrexate—colon cancer	2.05e-05	0.00111	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—colon cancer	2.05e-05	0.0011	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—colon cancer	2.03e-05	0.00109	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—colon cancer	2.02e-05	0.00109	CcSEcCtD
Topotecan—Asthenia—Capecitabine—colon cancer	2.02e-05	0.00109	CcSEcCtD
Topotecan—Anorexia—Methotrexate—colon cancer	1.99e-05	0.00107	CcSEcCtD
Topotecan—Pruritus—Capecitabine—colon cancer	1.99e-05	0.00107	CcSEcCtD
Topotecan—CYP3A4—digestive system—colon cancer	1.97e-05	0.0228	CbGeAlD
Topotecan—Diarrhoea—Capecitabine—colon cancer	1.92e-05	0.00104	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.92e-05	0.0121	CbGpPWpGaD
Topotecan—Musculoskeletal discomfort—Methotrexate—colon cancer	1.91e-05	0.00103	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—colon cancer	1.88e-05	0.00101	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.87e-05	0.0118	CbGpPWpGaD
Topotecan—Dyspnoea—Methotrexate—colon cancer	1.87e-05	0.001	CcSEcCtD
Topotecan—Dizziness—Capecitabine—colon cancer	1.86e-05	0.001	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.85e-05	0.0116	CbGpPWpGaD
Topotecan—Dyspepsia—Methotrexate—colon cancer	1.84e-05	0.000992	CcSEcCtD
Topotecan—ABCB1—epithelium—colon cancer	1.83e-05	0.0213	CbGeAlD
Topotecan—Decreased appetite—Methotrexate—colon cancer	1.82e-05	0.00098	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.81e-05	0.0114	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Methotrexate—colon cancer	1.81e-05	0.000973	CcSEcCtD
Topotecan—Fatigue—Methotrexate—colon cancer	1.8e-05	0.000972	CcSEcCtD
Topotecan—Pain—Methotrexate—colon cancer	1.79e-05	0.000964	CcSEcCtD
Topotecan—Vomiting—Capecitabine—colon cancer	1.79e-05	0.000962	CcSEcCtD
Topotecan—Rash—Capecitabine—colon cancer	1.77e-05	0.000954	CcSEcCtD
Topotecan—Dermatitis—Capecitabine—colon cancer	1.77e-05	0.000954	CcSEcCtD
Topotecan—Headache—Capecitabine—colon cancer	1.76e-05	0.000948	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—colon cancer	1.72e-05	0.000929	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.72e-05	0.0108	CbGpPWpGaD
Topotecan—Gastrointestinal pain—Methotrexate—colon cancer	1.71e-05	0.000921	CcSEcCtD
Topotecan—ABCB1—renal system—colon cancer	1.7e-05	0.0197	CbGeAlD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—ABCB1—colon cancer	1.68e-05	0.0106	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.67e-05	0.0105	CbGpPWpGaD
Topotecan—Nausea—Capecitabine—colon cancer	1.67e-05	0.000899	CcSEcCtD
Topotecan—Urticaria—Methotrexate—colon cancer	1.66e-05	0.000895	CcSEcCtD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	1.66e-05	0.0104	CbGpPWpGaD
Topotecan—Body temperature increased—Methotrexate—colon cancer	1.65e-05	0.000891	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—colon cancer	1.65e-05	0.000891	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—EP300—colon cancer	1.65e-05	0.0104	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.63e-05	0.0103	CbGpPWpGaD
Topotecan—ABCG2—lymph node—colon cancer	1.62e-05	0.0187	CbGeAlD
Topotecan—Hypersensitivity—Methotrexate—colon cancer	1.54e-05	0.00083	CcSEcCtD
Topotecan—Asthenia—Methotrexate—colon cancer	1.5e-05	0.000808	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.5e-05	0.00943	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.5e-05	0.00941	CbGpPWpGaD
Topotecan—Pruritus—Methotrexate—colon cancer	1.48e-05	0.000797	CcSEcCtD
Topotecan—CYP3A4—liver—colon cancer	1.47e-05	0.017	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.47e-05	0.00923	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	1.46e-05	0.00917	CbGpPWpGaD
Topotecan—Diarrhoea—Methotrexate—colon cancer	1.43e-05	0.000771	CcSEcCtD
Topotecan—ABCB1—lymphoid tissue—colon cancer	1.41e-05	0.0164	CbGeAlD
Topotecan—CYP3A4—Irinotecan Pathway—APC—colon cancer	1.4e-05	0.00879	CbGpPWpGaD
Topotecan—ABCB1—digestive system—colon cancer	1.39e-05	0.0162	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.39e-05	0.00872	CbGpPWpGaD
Topotecan—Dizziness—Methotrexate—colon cancer	1.38e-05	0.000745	CcSEcCtD
Topotecan—Vomiting—Methotrexate—colon cancer	1.33e-05	0.000716	CcSEcCtD
Topotecan—Rash—Methotrexate—colon cancer	1.32e-05	0.000711	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—colon cancer	1.32e-05	0.00071	CcSEcCtD
Topotecan—Headache—Methotrexate—colon cancer	1.31e-05	0.000706	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—EP300—colon cancer	1.3e-05	0.00819	CbGpPWpGaD
Topotecan—ABCB1—bone marrow—colon cancer	1.29e-05	0.0149	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.27e-05	0.00801	CbGpPWpGaD
Topotecan—Nausea—Methotrexate—colon cancer	1.24e-05	0.000669	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VEGFA—colon cancer	1.23e-05	0.00776	CbGpPWpGaD
Topotecan—ABCB1—vagina—colon cancer	1.23e-05	0.0143	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.23e-05	0.00775	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TP53—colon cancer	1.18e-05	0.00744	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	1.08e-05	0.00682	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	1.08e-05	0.00677	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.04e-05	0.00654	CbGpPWpGaD
Topotecan—ABCB1—liver—colon cancer	1.04e-05	0.012	CbGeAlD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	1e-05	0.00629	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	9.72e-06	0.00612	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	9.54e-06	0.006	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	9.53e-06	0.00599	CbGpPWpGaD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	8.47e-06	0.00533	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CA7—colon cancer	8.35e-06	0.00526	CbGpPWpGaD
Topotecan—ABCB1—lymph node—colon cancer	7.97e-06	0.00924	CbGeAlD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	7.66e-06	0.00482	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	7.4e-06	0.00466	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	7.26e-06	0.00456	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	6.63e-06	0.00417	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	6.23e-06	0.00392	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ODC1—colon cancer	5.06e-06	0.00318	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CHST5—colon cancer	5.06e-06	0.00318	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	4.98e-06	0.00313	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	4.63e-06	0.00291	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	4.58e-06	0.00288	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CA7—colon cancer	4.52e-06	0.00284	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	4.14e-06	0.00261	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—CASP3—colon cancer	4e-06	0.00252	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	3.92e-06	0.00247	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	3.82e-06	0.0024	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	3.68e-06	0.00231	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—VEGFA—colon cancer	3.4e-06	0.00214	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TGFB1—colon cancer	3.12e-06	0.00196	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.86e-06	0.0018	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.8e-06	0.00176	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CA7—colon cancer	2.78e-06	0.00175	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CHST5—colon cancer	2.74e-06	0.00172	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ODC1—colon cancer	2.74e-06	0.00172	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	2.5e-06	0.00157	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.13e-06	0.00134	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.98e-06	0.00124	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.92e-06	0.00121	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.9e-06	0.0012	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.86e-06	0.00117	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.77e-06	0.00111	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.72e-06	0.00108	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CHST5—colon cancer	1.69e-06	0.00106	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ODC1—colon cancer	1.69e-06	0.00106	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.68e-06	0.00105	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.54e-06	0.00097	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.54e-06	0.000968	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.51e-06	0.000949	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.43e-06	0.000897	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ABCB1—colon cancer	1.34e-06	0.000841	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TYMS—colon cancer	1.31e-06	0.000826	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.31e-06	0.000824	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.27e-06	0.000797	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.07e-06	0.000673	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PPARG—colon cancer	9.31e-07	0.000585	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS2—colon cancer	7.32e-07	0.00046	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TYMS—colon cancer	7.1e-07	0.000447	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—EP300—colon cancer	6.09e-07	0.000383	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PPARG—colon cancer	5.03e-07	0.000316	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CA—colon cancer	4.5e-07	0.000283	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ABCB1—colon cancer	4.46e-07	0.00028	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TYMS—colon cancer	4.38e-07	0.000275	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS2—colon cancer	3.96e-07	0.000249	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—AKT1—colon cancer	3.68e-07	0.000231	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—EP300—colon cancer	3.29e-07	0.000207	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PPARG—colon cancer	3.1e-07	0.000195	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS2—colon cancer	2.44e-07	0.000153	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CA—colon cancer	2.43e-07	0.000153	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—EP300—colon cancer	2.03e-07	0.000128	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—AKT1—colon cancer	1.99e-07	0.000125	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CA—colon cancer	1.5e-07	9.44e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—AKT1—colon cancer	1.23e-07	7.71e-05	CbGpPWpGaD
